LabMedica

Download Mobile App
Recent News Expo ADLM 2026 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Inverness Medical Innovations to Acquire Alere Medical

By HospiMedica staff writers
Posted on 31 Oct 2007
Inverness Medical Innovations (Waltham, MA, USA) has entered into an agreement to acquire Alere Medical, Inc., (Reno, NV, USA) for US$302 million.

Inverness Medical develops near-patient diagnostics, monitoring, and health management, enabling individuals to take charge of improving their health and quality of life. Focusing on rapid point-of-care diagnostics, Inverness' products concentrate on infectious disease, cardiology, oncology, drugs of abuse, and women's health.

Alere Medical provides specialized health management services focusing on a patient- centric, programmatic approach to comprehensive personal health support. Alere's integrated care monitoring system identifies and monitors all medium- and high-risk patients, and prioritizes those patients to facilitate efficient workflow.

Commenting on the transaction, Ron Zwanziger, CEO of Inverness, said The acquisition of Alere Medical is an exciting opportunity to enter the disease management industry, a move which fits naturally with our goal of enabling individuals to take charge of their health. Alere's expertise in patient monitoring and particularly in home chronic heart failure management complements our cardiac diagnostic technologies being developed at Biosite in San Diego and at Stirling Medical in Scotland. In addition, Alere brings with it exceptional management, a solid business platform, and strong revenues and profitability and is consistent well with our overall acquisition strategy.


Related Links:
Inverness Medical Innovations
Alere Medical, Inc

Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
HPV Molecular Test
BD Onclarity HPV Assay
Chromogenic Culture System
InTray™ COLOREX™ ECC

Latest Industry News

Collaboration Advances Extracellular Vesicle-Based Tests for Neurodegenerative Diseases
31 Oct 2007  |   Industry

Tempus to Acquire Personalis in $1.5 Billion Precision Oncology Deal
31 Oct 2007  |   Industry

Bruker Expands NGS Capabilities for Sepsis and Bloodstream Infections
31 Oct 2007  |   Industry



PURITAN MEDICAL